Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry (IPF/ILD-PRO)
Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Interstitial Lung Disease Prospective Outcomes (IPF-PRO/ILD-PRO) Registry
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the third phase of the registry begins, the IPF-PRO registry will enroll additional patients with idiopathic pulmonary fibrosis. This IPF-PRO registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) or of another chronic fibrosing interstitial lung disease (ILD) with progressive phenotype established at the enrolling centers. In addition, blood samples and chest image studies will be collected and banked for future research projects.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
This registry originally enrolled a total of 1002 participants newly diagnosed with IPF and continues to enroll patients with other chronic fibrosing ILDs with newly identified progressive phenotype to reach an enrollment of 1000 patients. Participants will be enrolled in three phases, (IPF-PRO and ILD-PRO) over a span of 8 years at approximately 50 sites experienced in the diagnosis and treatment of ILD in the United States. Enrollment for the original IPF cohort started in 2014 and ended in October 2018, with 1002 total participants enrolled. In the third phase of the registry new enrollment for patients with IPF will restart in 2023-2024 with the plan to enroll up to 1000 new IPF patients, for a total IPF enrollment of 2000. Enrollment for other chronic fibrosing ILDs with newly identified progressive phenotype cohort was initiated in February 2019 and will end when enrollment reaches 1000 participants with the potential of enrolling another 1000 participants with other chronic fibrosing ILDs with newly identified without a progressive phenotype. Data and samples will be collected from participants for approximately 5 years for the IPF cohort. For the chronic fibrosing ILD with progressive phenotype cohort, data and samples will be collected for a minimum of 3 years, up to approximately 5 years. Participant management and treatment decisions will be determined by participants and their health care professionals.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Rosalia Blanco
- Phone Number: 919-660-0890
- Email: rosalia.blanco@duke.edu
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Recruiting
- University of Alabama - Birmingham
-
Principal Investigator:
- Tejaswini Kulkarni, MD
-
Contact:
- Arnissa Hopson
- Phone Number: 205-934-1657
- Email: agoggins@uabmc.edu
-
-
Arizona
-
Tucson, Arizona, United States, 85721
- Recruiting
- University of Arizona
-
Principal Investigator:
- Sally A Suliman, MD
-
Contact:
- Daniel Castaneda-Beltran
- Phone Number: 602-827-2347
- Email: dcastanedabeltra@arizona.edu
-
-
California
-
Los Angeles, California, United States, 90033
- Recruiting
- University of Southern California
-
Contact:
- Lynn Fukusima
- Email: Lynn.Fukushima@med.usc.edu
-
Principal Investigator:
- Toby Maher, MD
-
Los Angeles, California, United States, 90024
- Recruiting
- University of California - Los Angeles
-
Principal Investigator:
- John Belperio, MD
-
Contact:
- Stephanie Roblero
- Phone Number: 310-627-2319
- Email: sroblero@mednet.ucla.edu
-
Stanford, California, United States, 94305
- Recruiting
- Stanford University
-
Principal Investigator:
- Rishi Raj, MD
-
Contact:
- Summer Zhu
- Phone Number: 650-724-5424
- Email: szhuye@stanford.edu
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- University of Colorado
-
Principal Investigator:
- Joyce Lee, MD
-
Contact:
- Olivia Brohl
- Phone Number: 303-724-0641
- Email: Olivia.brohl@cuanschutz.edu
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Recruiting
- Yale University
-
Principal Investigator:
- Mridu Gulati, MD
-
Contact:
- Maksym Minasyan
- Phone Number: 203-785-4177
- Email: maksym.minasyan@yale.edu
-
-
Florida
-
Gainesville, Florida, United States, 32610-3175
- Recruiting
- University of Florida
-
Contact:
- Lisbetty Lugo
- Email: lisbetty.lugo@medicine.ufl.edu
-
Principal Investigator:
- Diana Gomez Manjarres, MD
-
Tampa, Florida, United States, 33606
- Recruiting
- University of South Florida
-
Principal Investigator:
- Jose D Herazo-Maya, MD
-
Contact:
- Natasha Brown
- Email: nbrown@tgh.org
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Emory University
-
Contact:
- Tracy Halabi
- Phone Number: 404-712-7458
- Email: tracy.halaby@emory.edu
-
Principal Investigator:
- Srihari Veeraraghavan, MD
-
Austell, Georgia, United States, 30106
- Recruiting
- Piedmont Healthcare
-
Principal Investigator:
- Amy Case, MD
-
Contact:
- Munachi (Muna) Iwotor
- Phone Number: 404-291-9062
- Email: munachi.iwotor@piedmont.org
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- Recruiting
- University of Chicago
-
Principal Investigator:
- Mary Strek, MD
-
Contact:
- Vanita Patel
- Email: vpatel4@bsd.uchicago.edu
-
Evanston, Illinois, United States, 60611
- Recruiting
- Northwestern University
-
Contact:
- Phillip Cooper
- Phone Number: 312-503-0406
- Email: p-cooper@northwestern.edu
-
Principal Investigator:
- Bradford Bemiss, MD
-
Maywood, Illinois, United States, 60153
- Recruiting
- Loyola University Health System
-
Principal Investigator:
- Daniel Dilling, MD
-
Contact:
- Sloan White
- Email: swhite29@luc.edu
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- Terminated
- University of Kansas
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- Recruiting
- University of Kentucky
-
Principal Investigator:
- Girish Nair, MD
-
Contact:
- Kai Su
- Phone Number: 859-257-4501
- Email: kai.su@uky.edu
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Recruiting
- Tulane University
-
Principal Investigator:
- Joe Lasky, MD
-
Contact:
- Sandy Ditta
- Phone Number: 504-988-4040
- Email: sditta@tulane.edu
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Active, not recruiting
- University of Michigan
-
Detroit, Michigan, United States, 48202
- Recruiting
- Henry Ford Health
-
Contact:
- Deepti Naidu
- Phone Number: 313-916-8732
- Email: dnaidu1@HFHS.ORG
-
Principal Investigator:
- Asif Abdul Hameed, MD
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Recruiting
- University of Minnesota
-
Contact:
- Mandi DeGrote
- Phone Number: 612-626-7609
- Email: carl1032@umn.edu
-
Principal Investigator:
- Hyum Kim, MD
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216
- Recruiting
- University of Mississippi Medical Center
-
Principal Investigator:
- Kimberly Dobbs, MD
-
Contact:
- Leadeashia Brackett
- Phone Number: 601-496-7814
- Email: lbrackett@umc.edu
-
-
Missouri
-
St Louis, Missouri, United States, 63110
- Recruiting
- Washington University
-
Principal Investigator:
- Tonya Russell, MD
-
Contact:
- Mona Noroozi
- Phone Number: 314-362-3705
- Email: mnoroozi@wustl.edu
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Weill Medical College of Cornell University
-
Principal Investigator:
- Kerri Aronson, MD
-
Contact:
- Alicia Morris
- Phone Number: 646-692-2741
- Email: ajm2017@med.cornell.edu
-
New York, New York, United States, 10016
- Active, not recruiting
- NYU Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- Recruiting
- UNC Chapel Hill
-
Principal Investigator:
- Jason Lobo, MD
-
Contact:
- Jackson Pettee
- Email: Jackson_pettee@med.unc.edu
-
Durham, North Carolina, United States, 27705
- Recruiting
- Duke University
-
Principal Investigator:
- Lake Morrison, MD
-
Contact:
- Lauren Gray
- Phone Number: 919-684-7317
- Email: lauren.gray@duke.edu
-
Greensboro, North Carolina, United States, 27403
- Recruiting
- Pulmonix LLC
-
Principal Investigator:
- Murali Ramaswamy, MD
-
Contact:
- Mei Zheng
- Phone Number: 336-522-8870
- Email: mei.zheng@pulmonix.com
-
Wilmington, North Carolina, United States, 28401
- Terminated
- PMG Research
-
Winston-Salem, North Carolina, United States, 27157
- Recruiting
- Wake Forest Baptist Health
-
Contact:
- Bob Hmieleski
- Phone Number: 336-713-8550
- Email: bhmieles@wakehealth.edu
-
Principal Investigator:
- Andrew Namen, MD
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- Active, not recruiting
- University of Cincinnati Medical Center
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic
-
Principal Investigator:
- Brian Southern, MD
-
Contact:
- Ron Wehrmann
- Phone Number: 2164450574
- Email: wehrmar@ccf.org
-
Columbus, Ohio, United States, 43210
- Recruiting
- The Ohio State University
-
Contact:
- Benjamin Hood
- Email: benjamin.hood2@osumc.edu
-
Principal Investigator:
- John Odackal
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Recruiting
- University of Oklahoma
-
Principal Investigator:
- Jad Kebbe, MD
-
Contact:
- Maria Mason
- Phone Number: 405-271-6173
- Email: maria-l-mason@ouhsc.edu
-
-
Oregon
-
Portland, Oregon, United States, 97220
- Recruiting
- Oregon Clinic
-
Principal Investigator:
- David Hotchkin, MD
-
Contact:
- Meg Day
- Phone Number: 503-963-3182
- Email: mday@orclinic.com
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Recruiting
- Penn State College of Medicine - Hershey
-
Principal Investigator:
- Rebecca Bascom, MD
-
Contact:
- Tim Sheehan
- Phone Number: 717-531-2925
- Email: tsheehan@pennstatehealth.psu.edu
-
Philadelphia, Pennsylvania, United States, 19140
- Recruiting
- Temple University
-
Principal Investigator:
- Rachel Criner, MD
-
Contact:
- Luis Cardenas-Osorio
- Phone Number: 215-707-3311
- Email: Luis.Cardenas-Osorio@tuhs.temple.edu
-
Philadelphia, Pennsylvania, United States, 19144
- Recruiting
- Thomas Jefferson University
-
Principal Investigator:
- Ross Summer, MD
-
Contact:
- Ramya Talluri, BSN, RN
- Email: RamyaPriya.Talluri@jefferson.edu
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Recruiting
- Medical University of South Carolina
-
Principal Investigator:
- Timothy Whelan, MD
-
Contact:
- Audra Wiser
- Email: wisera@musc.edu
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Recruiting
- Vanderbilt University
-
Contact:
- James Del Greco
- Phone Number: 615-343-7068
- Email: james.del.greco@vumc.org
-
Principal Investigator:
- Justin Hewlett, MD
-
-
Texas
-
Dallas, Texas, United States, 75235
- Recruiting
- University of Texas Southwestern
-
Principal Investigator:
- John Fitzgerald, MD
-
Contact:
- Meagan Galvan
- Phone Number: 214-645-6489
- Email: Maegan.Galvan@UTSouthwestern.edu
-
Dallas, Texas, United States, 75246
- Recruiting
- Baylor University Medical Center at Dallas
-
Principal Investigator:
- Yolanda Mageto, MD
-
Contact:
- Mary Alayo
- Phone Number: 214-820-6276
- Email: Mary.Alayo@BSWHealth.org
-
Houston, Texas, United States, 77030
- Recruiting
- Baylor College of Medicine
-
Principal Investigator:
- Ivan Rosas, MD
-
Contact:
- Maria C Perea
- Email: Maria.Perea@bcm.edu
-
Houston, Texas, United States, 77030
- Recruiting
- Houston Methodist Lung Center
-
Principal Investigator:
- Zeenat Safdar, MD
-
Contact:
- Laura Valecillos Loukidis
- Phone Number: 346-238-4637
- Email: lvvalecillosloukidis@houstonmethodist.org
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas Health Science Center At Houston
-
Principal Investigator:
- Rodeo Abrencillo, MD
-
Contact:
- Beverly Rios
- Phone Number: 713-486-6152
- Email: Beverly.Rios@uth.tmc.edu
-
-
Utah
-
Salt Lake City, Utah, United States, 84108
- Recruiting
- University of Utah
-
Contact:
- Adeline Langer
- Phone Number: 801-581-5811
- Email: adeline.langer@hsc.utah.edu
-
Principal Investigator:
- Mary Beth Langer, MD
-
Salt Lake City, Utah, United States, 84111
- Recruiting
- Intermountain Health
-
Contact:
- Aisha Skowyra
- Phone Number: 801-507-2439
- Email: Aisha.fairclough@imail.org
-
Principal Investigator:
- Erin Blackstock, MD
-
-
Vermont
-
Colchester, Vermont, United States, 05446
- Active, not recruiting
- University of Vermont Lung Center
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- Active, not recruiting
- University from Virginia
-
Falls Church, Virginia, United States, 22042-3307
- Recruiting
- Inova Health Care Services
-
Contact:
- Taruni Maganti
- Phone Number: 703-776-3230
- Email: Taruni.Maganti@inova.org
-
Principal Investigator:
- Jared Wilkinson, MD
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Active, not recruiting
- The Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Subjects with a new diagnosis of IPF or a non- IPF chronic fibrosing ILD established at the time of enrollment in the registry are eligible for participation in the IPF-PRO/ILD-PRO registry if the participant meets the selection criteria.
Description
Inclusion Criteria:
-
Willing and able to provide informed consent
-
Established a new diagnosis (within 12 months) of IPF by the enrolling center.
-
Age 21 years or older, or
-
Diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype during the last 24 months by the enrolling center that meets the following criteria:
-
Chronic fibrosing ILD as defined by reticular abnormality with traction bronchiectasis with or without honeycombing confirmed by chest HRCT scan and/or lung biopsy.
-
Progressive phenotype as defined by fulfilling at least one of the criteria below of fibrotic changes (progression set point) within the last 24 months regardless of treatment considered appropriate in individual ILDs (8):
- decline in FVC % predicted (% pred) based on ≥10% relative decline
- decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with worsening of respiratory symptoms as assessed by the site investigator
- decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator
- decline in DLCO % pred based on≥ 10% relative decline
- worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator independent of FVC change.
-
The relative decline for FVC % predicted is calculated using the formula:
Relative Decline= (FVC % Pred (Reference)-FVC % Pred (Screening))/(FVC % Pred (Reference))×100%, where FVC % Pred (Reference) is the greatest measurement of FVC % predicted in the 24 months prior to screening and FVC % Pred (Screening) is the measurement of FVC % predicted at screening.
The relative decline for DLCO % predicted is calculated using the formula:
Relative Decline= (DLCO % Pred (Reference)-DLCO % Pred (Screening))/(DLCO % Pred (Reference))×100%, Where DLCO % Pred (Reference) is the greatest measurement of DLCO % Pred in the 24 months prior to screening and DLCO % Pred (Screening) is the measurement of DLCO % Pred at screening
Exclusion Criteria:
- Malignancy, treated or untreated, other than skin or early -stage prostate cancer, within the past 5 years
- Currently listed for lung transplantation at the time of enrollment
- Currently enrolled in an interventional clinical trial at the time of enrollment in this registry
- For the additional IPF cohort of 1000 individuals, previous enrollment in this registry.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Subjects with a new IPF diagnosis
Subjects with a new diagnosis of IPF established at the time of enrollment in the registry |
|
Subjects with a non-IPF ILD diagnosis
Subjects with a diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype |
|
New Subjects with a new IPF diagnosis
Subjects with a new diagnosis of IPF established at the time of enrollment in the registry not previously enrolled in the registry. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Data on natural history of IPF & non-IPF chronic fibrosing ILD
Time Frame: End of Study (3 years after last patient will be enrolled)
|
Characterize and describe the natural history of patients with a recent confirmed diagnosis of IPF, with emphasis on demographics, co-morbidities, medications, and risks for disease progression or death. |
End of Study (3 years after last patient will be enrolled)
|
|
Data on current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD
Time Frame: End of Study (3 years after last patient will be enrolled)
|
Understand the current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD |
End of Study (3 years after last patient will be enrolled)
|
|
Data on impact of IPF & non- IPF chronic fibrosing ILD on patient quality of life.
Time Frame: End of Study (3 years after last patient will be enrolled)
|
Describe the impact of IPF & non- IPF chronic fibrosing ILD on patient quality-of-life (QOL). |
End of Study (3 years after last patient will be enrolled)
|
|
Blood samples for future research.
Time Frame: End of Study (3 years after last patient will be enrolled)
|
Collect longitudinal bio-samples for future research on disease presentation, progression, and subject response to clinical interventions. |
End of Study (3 years after last patient will be enrolled)
|
|
HRCT images for future research (for non-IPF chronic fibrosing ILD, and new IPF patients cohort)
Time Frame: End of Study (3 years after last patient will be enrolled)
|
Collect longitudinal HRCT images for future research |
End of Study (3 years after last patient will be enrolled)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Data on management practices compared to existing guidelines.
Time Frame: End of Study (3 years after last patient will be enrolled)
|
Compare disease-specific management practices with existing guidelines. |
End of Study (3 years after last patient will be enrolled)
|
|
Data on center-specific practices on outcomes.
Time Frame: End of Study (3 years after last patient will be enrolled)
|
Determine the influence of center-specific practices on patient outcomes. |
End of Study (3 years after last patient will be enrolled)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Scott Palmer, MD, Duke Clinical Research Institute, Duke University
Publications and helpful links
General Publications
- Swaminathan AC, Hellkamp AS, Neely ML, Bender S, Paoletti L, White ES, Palmer SM, Whelan TPM, Dilling DF; Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry investigators. Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry. Ann Am Thorac Soc. 2022 Jun;19(6):981-990. doi: 10.1513/AnnalsATS.202105-589OC.
- Kim HJ, Snyder LD, Neely ML, Hellkamp AS, Hotchkin DL, Morrison LD, Bender S, Leonard TB, Culver DA; IPF-PRO Registry investigators. Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry. Lung. 2022 Feb;200(1):21-29. doi: 10.1007/s00408-021-00506-x. Epub 2022 Jan 7.
- de Andrade JA, Kulkarni T, Neely ML, Hellkamp AS, Case AH, Culver DA, Guntupalli K, Bender S, Conoscenti CS, Snyder LD; IPF-PRO Registry Investigators. Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respir Res. 2022 Jan 7;23(1):3. doi: 10.1186/s12931-021-01921-7.
- Kim HJ, Snyder LD, Adegunsoye A, Neely ML, Bender S, White ES, Conoscenti CS, Strek ME; IPF-PRO Registry Investigators. Hospitalizations in patients with idiopathic pulmonary fibrosis. Respir Res. 2021 Sep 30;22(1):257. doi: 10.1186/s12931-021-01851-4.
- Salisbury ML, Conoscenti CS, Culver DA, Yow E, Neely ML, Bender S, Hartmann N, Palmer SM, Leonard TB; IPF-PRO Registry principal investigators as follows. Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry. Ann Am Thorac Soc. 2020 Nov;17(11):1413-1423. doi: 10.1513/AnnalsATS.201912-880OC.
- Fan Y, Bender SD, Conoscenti CS, Davidson-Ray L, Cowper PA, Palmer SM, de Andrade JA; IPF-PRO Registry Investigators. Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Chest. 2020 Jun;157(6):1522-1530. doi: 10.1016/j.chest.2019.12.041. Epub 2020 Jan 29.
- O'Brien EC, Hellkamp AS, Neely ML, Swaminathan A, Bender S, Snyder LD, Culver DA, Conoscenti CS, Todd JL, Palmer SM, Leonard TB; IPF-PRO Registry investigators. Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry. Chest. 2020 May;157(5):1188-1198. doi: 10.1016/j.chest.2019.11.042. Epub 2020 Jan 15.
- Todd JL, Neely ML, Overton R, Durham K, Gulati M, Huang H, Roman J, Newby LK, Flaherty KR, Vinisko R, Liu Y, Roy J, Schmid R, Strobel B, Hesslinger C, Leonard TB, Noth I, Belperio JA, Palmer SM; IPF-PRO Registry investigators. Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry. Respir Res. 2019 Oct 22;20(1):227. doi: 10.1186/s12931-019-1190-z.
- Snyder L, Neely ML, Hellkamp AS, O'Brien E, de Andrade J, Conoscenti CS, Leonard T, Bender S, Gulati M, Culver DA, Kaner RJ, Palmer S, Kim HJ; IPF-PRO Registry investigators. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. Respir Res. 2019 May 30;20(1):105. doi: 10.1186/s12931-019-1043-9.
- O'Brien EC, Durheim MT, Gamerman V, Garfinkel S, Anstrom KJ, Palmer SM, Conoscenti CS. Rationale for and design of the Idiopathic Pulmonary Fibrosis-PRospective Outcomes (IPF-PRO) registry. BMJ Open Respir Res. 2016 Jan 11;3(1):e000108. doi: 10.1136/bmjresp-2015-000108. eCollection 2016.
- Swaminathan AC, Weber JM, Todd JL, Palmer SM, Neely ML, Whelan TP, Kim GHJ, Leonard TB, Goldin J. Extent of lung fibrosis is of greater prognostic importance than HRCT pattern in patients with progressive pulmonary fibrosis: data from the ILD-PRO registry. Respir Res. 2025 Feb 28;26(1):73. doi: 10.1186/s12931-025-03136-6.
- Oldham JM, Neely ML, Wojdyla DM, Gulati M, Li P, Patel DC, Palmer SM, Todd JL; IPF-PRO Registry Investigators. Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis. Chest. 2025 Aug;168(2):415-422. doi: 10.1016/j.chest.2025.02.018. Epub 2025 Feb 26.
- Sack C, Wojdyla DM, MacMurdo MG, Gassett A, Kaufman JD, Raghu G, Redlich CA, Li P, Olson AL, Leonard TB, Todd JL, Neely ML, Snyder LD, Gulati M; IPF-PRO Registry investigators. Long-Term Air Pollution Exposure and Severity of Idiopathic Pulmonary Fibrosis: Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Ann Am Thorac Soc. 2025 Mar;22(3):378-386. doi: 10.1513/AnnalsATS.202404-382OC.
- Wang L, Wu P, Liu Y, Patel DC, Leonard TB, Zhao H. Clustering-aided prediction of outcomes in patients with idiopathic pulmonary fibrosis. Respir Res. 2024 Oct 23;25(1):383. doi: 10.1186/s12931-024-03015-6.
- Lobo LJ, Liu Y, Li P, Ramaswamy M, Swaminathan AC, Veeraraghavan S, Fan Y, Neely ML, Palmer SM, Olson AL; ILD-PRO Registry investigatorsdagger. Design and baseline characteristics of the ILD-PRO registry in patients with progressive pulmonary fibrosis. BMC Pulm Med. 2024 Sep 27;24(1):468. doi: 10.1186/s12890-024-03247-8.
- Summer R, Todd JL, Neely ML, Lobo LJ, Namen A, Newby LK, Shafazand S, Suliman S, Hesslinger C, Keller S, Leonard TB, Palmer SM, Ilkayeva O, Muehlbauer MJ, Newgard CB, Roman J. Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respir Res. 2024 Jan 25;25(1):58. doi: 10.1186/s12931-023-02644-7.
- Neely ML, Hellkamp AS, Bender S, Todd JL, Liesching T, Luckhardt TR, Oldham JM, Raj R, White ES, Palmer SM. Lung function trajectories in patients with idiopathic pulmonary fibrosis. Respir Res. 2023 Aug 24;24(1):209. doi: 10.1186/s12931-023-02503-5.
- Ruan P, Todd JL, Zhao H, Liu Y, Vinisko R, Soellner JF, Schmid R, Kaner RJ, Luckhardt TR, Neely ML, Noth I, Porteous M, Raj R, Safdar Z, Strek ME, Hesslinger C, Palmer SM, Leonard TB, Salisbury ML. Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression. Respir Res. 2023 May 31;24(1):141. doi: 10.1186/s12931-023-02435-0.
- Menon AA, Gansen B, Mulder H, Neely ML, Papavasileiou P, Salisbury ML, Southern BD, Hesslinger C, Leonard TB, Meissner F, Todd JL. Mass spectrometry-based peripheral blood proteomics for biomarker discovery in idiopathic pulmonary fibrosis. Respir Res. 2025 Oct 22;26(1):294. doi: 10.1186/s12931-025-03377-5.
- Shetty S, Swaminathan AC, Li P, Neely ML, Olson AL, Snyder LD; ILD-PRO Registry investigators. Workplace Productivity Loss in Patients with Progressive Pulmonary Fibrosis: Data from the ILD-PRO Registry. Lung. 2026 May 27;204(1):32. doi: 10.1007/s00408-026-00895-x.
- Swaminathan AC, Mulder H, Neely ML, Schmid R, Belperio JA, Patel NM, Palmer SM, Todd JL. Expression of complement pathway genes is associated with progression of idiopathic pulmonary fibrosis. Respir Res. 2026 Mar 25;27(1):196. doi: 10.1186/s12931-026-03641-2.
- Neely ML, Todd JL, Snyder LD, Li P, Olson AL; IPF-PRO Registry Investigators *. Trajectories of Health-Related Quality of Life in Patients With Idiopathic Pulmonary Fibrosis. CHEST Pulm. 2024 Dec 27;3(4):100133. doi: 10.1016/j.chpulm.2024.100133. eCollection 2025 Dec.
- MacMurdo MG, Wojdyla DM, Gassett A, Kaufman JD, Raghu G, Redlich CA, Patel DC, Neely ML, Snyder LD, Gulati M, Sack C; IPF-PRO Registry investigators. Short-term air pollution exposure and hospitalizations in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Ann Am Thorac Soc. 2026 Sep 12:aaoag285. doi: 10.1093/annalsats/aaoag285. Online ahead of print.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Pro00046131
- 1199.174 (Other Identifier: DCRI)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.